Prokidney’s Long-Term Study on REACT Therapy: A Potential Game-Changer for CKD
Prokidney Corp. ((PROK)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Prokidney Corp. is conducting a long-term follow-up study titled ‘A Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy From Studies RMCL-002, REGEN-003, REGEN-004.’ The study aims to assess the long-term safety of REACT injections on renal function in patients with chronic kidney disease (CKD), particularly those with diabetic kidney disease. This research is significant as it could offer new insights into the management of CKD, a condition with limited treatment options.
The intervention being tested is the Renal Autologous Cell Therapy (REACT), a biological treatment designed to improve kidney function. Participants previously treated with REACT in earlier studies will be observed for long-term safety outcomes.
This observational study follows a cohort model with a prospective time perspective. It involves collecting and storing biological samples for future research, allowing participants the option to opt out of long-term specimen storage.
The study began on June 15, 2023, with recruitment currently ongoing. The primary completion and estimated study completion dates are set for May 27, 2025. These timelines are crucial for tracking the study’s progress and potential impact on treatment protocols.
The update on this study could influence Prokidney’s stock performance positively, as successful outcomes may enhance investor confidence and position the company as a leader in CKD treatment innovation. The study’s progress is particularly relevant in the context of a competitive market where advancements in kidney disease therapies are highly anticipated.
The study is ongoing, with further details available on the ClinicalTrials portal.
